NCT03324360: Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

NCT03324360
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have at least 1 intracranial metastasis greater than or equal to 1 cm in size amenable to stereotactic radiosurgery or radiotherapy
Exclusions: Patients with prior brain radiotherapy for the lesion to be imaged in the study
https://ClinicalTrials.gov/show/NCT03324360

Comments are closed.

Up ↑